Cirmtuzumab

Summary

Cirmtuzumab (CHEMBL4297728) is a phase-3 clinical-stage antibody; indicated across 10 conditions including b-cell chronic lymphocytic leukemia and neoplasm of mature b-cells.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 10 conditions
• Clinical trials: 17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297728
Name	Cirmtuzumab
Type	Antibody
Max phase	3

Also known as: Cirmtuzumab, UC-961, Zilovertamab, CIRMTUZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
neoplasm of mature B-cells	2	MONDO:0004949	EFO:0000096
diffuse large B-cell lymphoma	2	MONDO:0018905	EFO:0000403
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
triple-negative breast carcinoma	2	MONDO:0005494	EFO:0005537
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
ovarian cancer	2	MONDO:0008170	MONDO:0008170
urothelial carcinoma	1	MONDO:0040679	EFO:0008528

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE2	6
PHASE1	5
PHASE1/PHASE2	3
PHASE3	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05139017	PHASE2/PHASE3	RECRUITING	A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT06717347	PHASE3	RECRUITING	A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT05431179	PHASE3	WITHDRAWN	A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT04501939	PHASE2	ACTIVE_NOT_RECRUITING	Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
NCT05406401	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
NCT05458297	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05562830	PHASE1/PHASE2	RECRUITING	A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
NCT06395103	PHASE1/PHASE2	RECRUITING	Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06890884	PHASE2	RECRUITING	A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT03088878	PHASE1/PHASE2	COMPLETED	A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
NCT04504916	PHASE2	TERMINATED	A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
NCT05144841	PHASE2	COMPLETED	A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
NCT02222688	PHASE1	COMPLETED	UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT02776917	PHASE1	COMPLETED	Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
NCT02860676	PHASE1	COMPLETED	Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
NCT03833180	PHASE1	COMPLETED	A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
NCT05156905	PHASE1	TERMINATED	Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).